Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non–small-cell Lung Cancer

Ebaa Al-Obeidi, Tianhong Li, Karen Kelly

Research output: Contribution to journalArticlepeer-review

2 Scopus citations
Original languageEnglish (US)
JournalClinical lung cancer
StateAccepted/In press - Jan 1 2019


  • Lung adenocarcinoma
  • Never smoking women
  • Oncogenic driven tumor
  • Tyrosine kinase inhibitor
  • Untreated metastatic disease

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this